Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Want to know more about chronic inflammatory diseases and access helpful resources like our doctor discussion guide? Click to take the #AdvantageHers questionnaire and learn more now! https://t.co/nogAve4ECC
— UCB News (@ucb_news) 21.10.2021 -
#UCB is licensing the #BoneBot to ImageBiopsy Lab to bring the patient identification tool to market by 2023! #BoneBot detects asymptomatic fractures in the spine, which can otherwise go unrecognised and unreported. Richard Ljuhar, CEO of ImageBiopsy Lab
— UCB News (@ucb_news) 21.10.2021 -
As part of #UCB’s digital business transformation, we are licensing the #BoneBot to ImageBiopsyLab to bring the innovative identification tool to market by 2023. Emmanuel Caeymaex, Head of Immunology & US Solutions and Executive Vice President at #UCB
— UCB News (@ucb_news) 21.10.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
